Enfusion Other Current Liab from 2010 to 2024

ENFN Stock  USD 9.41  0.03  0.32%   
Enfusion Other Current Liabilities yearly trend continues to be very stable with very little volatility. Other Current Liabilities is likely to drop to about 6.4 M. During the period from 2010 to 2024, Enfusion Other Current Liabilities quarterly data regression pattern had sample variance of 17.7 T and median of  169,000. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
11.4 M
Current Value
6.4 M
Quarterly Volatility
4.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion main balance sheet or income statement drivers, such as Tax Provision of 867 K, Net Interest Income of 1.7 M or Depreciation And Amortization of 4.7 M, as well as many exotic indicators such as Price To Sales Ratio of 4.66, Dividend Yield of 0.0034 or PTB Ratio of 16.74. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
This module can also supplement Enfusion's financial leverage analysis and stock options assessment as well as various Enfusion Technical models . Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Latest Enfusion's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Enfusion over the last few years. It is Enfusion's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enfusion's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Enfusion Other Current Liab Regression Statistics

Arithmetic Mean2,469,908
Geometric Mean492,212
Coefficient Of Variation170.41
Mean Deviation3,361,732
Median169,000
Standard Deviation4,209,030
Sample Variance17.7T
Range11.5M
R-Value0.72
Mean Square Error9.1T
R-Squared0.52
Significance0
Slope681,123
Total Sum of Squares248T

Enfusion Other Current Liab History

20246.4 M
202311.4 M
202211.7 M
20215.6 M
2020266 K

About Enfusion Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Enfusion income statement, its balance sheet, and the statement of cash flows. Enfusion investors use historical funamental indicators, such as Enfusion's Other Current Liab, to determine how well the company is positioned to perform in the future. Although Enfusion investors may use each financial statement separately, they are all related. The changes in Enfusion's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enfusion's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Enfusion Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Enfusion. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities11.4 M6.4 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
Note that the Enfusion information on this page should be used as a complementary analysis to other Enfusion's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Enfusion Stock analysis

When running Enfusion's price analysis, check to measure Enfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enfusion is operating at the current time. Most of Enfusion's value examination focuses on studying past and present price action to predict the probability of Enfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enfusion's price. Additionally, you may evaluate how the addition of Enfusion to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Money Managers
Screen money managers from public funds and ETFs managed around the world
CEOs Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is Enfusion's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.94)
Earnings Share
0.02
Revenue Per Share
2.055
Quarterly Revenue Growth
0.173
Return On Assets
0.0331
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.